Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kimberly A Tipton

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Molecular Cell|November 26, 2008
In vivo monitoring of the prion replication cycle reveals a critical role for Sis1 in delivering substrates to Hsp104Kimberly A Tipton, Katherine J Verges, Jonathan S Weissman
Journal of Bacteriology|August 4, 2005
Shigella dysenteriae ShuS promotes utilization of heme as an iron source and protects against heme toxicityElizabeth E Wyckoff, Gregory F Lopreato, Kimberly A Tipton, et al.
Cell|January 1, 2003
Directed evolution of substrate-optimized GroEL/S chaperoninsJue D Wang, Christophe Herman, Kimberly A Tipton, et al.
Cancer Immunology Research|October 12, 2021
Conditional PD-1/PD-L1 Probody Therapeutics Induce Comparable Antitumor Immunity but Reduced Systemic Toxicity Compared with Traditional Anti-PD-1/PD-L1 AgentsHikmat H Assi, Chihunt Wong, Kimberly A Tipton, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Molecular Cell|November 26, 2008
In vivo monitoring of the prion replication cycle reveals a critical role for Sis1 in delivering substrates to Hsp104Kimberly A Tipton, Katherine J Verges, Jonathan S Weissman
Journal of Bacteriology|August 4, 2005
Shigella dysenteriae ShuS promotes utilization of heme as an iron source and protects against heme toxicityElizabeth E Wyckoff, Gregory F Lopreato, Kimberly A Tipton, et al.
Cell|January 1, 2003
Directed evolution of substrate-optimized GroEL/S chaperoninsJue D Wang, Christophe Herman, Kimberly A Tipton, et al.
Cancer Immunology Research|October 12, 2021
Conditional PD-1/PD-L1 Probody Therapeutics Induce Comparable Antitumor Immunity but Reduced Systemic Toxicity Compared with Traditional Anti-PD-1/PD-L1 AgentsHikmat H Assi, Chihunt Wong, Kimberly A Tipton, et al.
Pageof 1